Hepatitis B Virus [HBV] Market Synopsis

Hepatitis B Virus [HBV} Market Size Was Valued at USD 4.74 Billion in 2023 and is Projected to Reach USD 6.76 Billion by 2032, Growing at a CAGR of 4.03% From 2024-2032

Hepatitis B is a DNA virus that causes Hepatitis an inflammation of the liver that occurs in two forms – acute and chronic. It can only be contracted by touching infected blood or other body fluids like semen or vaginal fluid. Moreover, it is often claimed the chronic infection with the virus poses certain risks such as cirrhosis of the liver and liver cancer. Florence and Streitenberger also stated that vaccination is the most feasible method to avoid getting infected with HBV.

• HBV product market is relatively large and growing rapidly mainly because the disease continues to pose a substantial health burden globally. Hepatitis B virus is a liver infection known as HBV which is a more serious problem for health care systems in the world because its incidence is highest in Asia and Africa. On the condition of ongoing infection, chronic HBV infection may continue to be a major concern because of the large number of people infected before the vaccine was developed and instituted widely. These are ilks vaccines, antiviral drugs, diagnostic tests and monitoring products which are all important in preventing, diagnosing and managing he HBV.
• Drugs used in the management of HBV are vaccines since products like Engerix-B, Recombivax HB, and Heplisav-B are vaccines that enable clients to avoid getting infected. These vaccines are essential measures towards the prevention and control of HBV especially among newborns as well as other at-risk groups. Overall, HBV remains a significant cause of disease, death, and disability; however, the introduction of the HBV vaccine into national immunization programs has significantly describe the extent of the difference in new infections. But while goals like global vaccination coverage remain essential, issues like vaccine reluctance, hesitance and hard-to-reach communities persist as barriers to access.
• However, the existing market of HBV treatment are several antiviral drugs the aim of which is to control viral reproduction and decrease the degree of liver injury. Unlike treatment for acute infection, the management of chronic HBV infection involves pharmacological therapy using Tenofovir, Entecavir, and Pegylated interferon. These treatments are crucial in the decline of developing cirrhosis and hepatocellular carcinoma, thus enhancing patient prognoses. However, the search for a more effective cure for HBV has not been effectively arrived at yet, forming the basis of further research in this particular area. Current treatment measures include: Interferons and nucleoside analogs that inhibit HBV replication are prescribed to cure chronic hepatitis B; Further treatment methods under development include: gene editing and therapeutic vaccines.
• The diagnostic segment of the HBV market is equally significant and serves to show that the virus has infected the patient as well as the extent of the infection and the health of the liver. These Diagnostics is necessary for consulting over the treatment methods of the diseases, and for tracking the evolution of the ailments. Advancements in this area, including point of care technology and next generation sequencing are rising the sensitivity and availability of HBV diagnosis thus helping in accurate early assessment of the virus.
• Market dynamics are also defined by their characteristics such as regulation policies, health care facility and systems and the economic factors. Approvals from regulatory authorities like FDA and EMA are also considered extremely influential while introducing a new HBV product into the market and thereby its uptake. Moreover, the epidemiological studies and finances of the WHO and the CDC are essential in ensuring the adequacy of HBV control and management programs internationally.
• The economic aspect of a country also offers an explanation to the price trends of the HBV, high-income countries have strong financial ability and put emphasis on the prevention and treatment of HBV, while the low and middle-income countries have the constrain of financial strength to provide proper interventions. Funding for HBV therefore remains a major challenge and global health partnerships and funding mechanisms remain critical in filling this gap and meet the needs of patients.
• The market for HBV is vibrant through advancement in the provision and development of vaccination, treatment, and diagnosis where major public health concerns and research contribute to the development of the market. Despite the advances in combating HBV infection, the residual and persistent difficulties lie at the issue of eradicating it completely as well as ensuring equal availability of treatments to the world’s population. Therefore, new therapeutic approaches for the treatment of HBV and better diagnostic methods, stronger cooperation between HBV infected countries with developed countries, and efforts to overcome the current difficulties will determine the further developments of the HBV market.

Hepatitis B Virus [HBV] Market Trend Analysis

Increasing Adoption of Vaccination Programs

One of the major trends that have been reflected with regard to the HBV market is the increased demand for vaccination programs. Efforts in public health and awareness program have made people more aware and health departments more aggressive in the vaccination campaigns resulting in decrease in infection rate of HBV worldwide. HBV vaccination has become an important part of governments’ and health organizations’ goals as they focus on preventing the disease in the territories where it is rapidly spreading. This has a twofold effect of reducing the incidence of HBV but also containing the steady health costs involved in managing chronically infected persons. Thus, the market has shifted towards preventive medicine with drug makers directing their efforts on the creation of better vaccines and congenial therapies. The fact that he was born in the year 1984 is evident and this has made it possibly not to receive vaccination programs for controlling HBV which if implemented would improve the health standards across the globe.

Expansion of Preventive Healthcare Services

That is, the key trend within the HBV market in terms of preventive healthcare services is their expansion due to growing awareness and access to vaccinations and screenings. As a result of this, the governments and health sector all over the world is encouraging early detection and vaccination to prevent the spread of HBV. This has culminated in increased funding and investments in public health campaigns entailing free or subsidized vaccinations, mass attitude transformation fairs, along with wider population screening activities especially to the vulnerable groups. Improved diagnostics, developments regarding better and advanced vaccines are also driving the market. Moreover, there are more federal and state initiatives and partnerships between the public and private sectors driving more development of new ideas and increasing the opportunity for people to get preventative access to affordable and approximately fully glomerulus-invasive HBV.

Hepatitis B Virus [HBV] Market  Segment Analysis:

Hepatitis B Virus [HBV] Market is Segmented based on Type and Application.

By Type, Hepatitis B virus (HBV) DNA Testing segment is expected to dominate the market during the forecast period

• This market includes the diagnostic tools used to identify HBV DNA within a specific sample volume in blood of a patient. This is especially important for correct identification and further observation of the HBV infections, evaluation of anti-viral treatment and prognosis of the diseases. The test to detect HBV DNA has emerged to be a popular market because of the constant awareness of the disease, the growth of the virus, and technological growth in Molecular diagnostic tools. The market also has growth demands arising from the need of early diagnosis and efficient control of chronic HBV infections to prevent hepatic disorders like cirrhosis or HCC. Major market participants are striving to produce superior products with high sensitivity, specificity, and speed of testing as consumers’ need for accurate and efficient diagnostic tools increases.
• Such examination, coupled with other drivers like regulatory approval and affiliations between healthcare providers and diagnostic companies also augments market growth. HBV DNA testing has further prospective to improve its performance through elaborative technologies, including real-time PCR and next-generation sequencing to be an influential tool in tackling hepatitis B universally.

 By Application, Hospital segment held the largest share in 2023

• The analysis of the HBV market based on its application and type presents diverse trends that mark the market. This area is widely developed, especially in hospitals because many people infected with HBV require diagnostics and effective treatment in addition to necessary medical care. Hospitals are centers which diagnose, treat, and manage HBV; the hospitals in question provide services such as testing and antiviral treatment. Clinics have their unique importance as they are close-to-community institutions for HBV screening, vaccination, and primary level health care. Often, the organizational settings of these settings are concerned with early identification or manifestations of disease and preventive measures, targeted at clients who are considered high-risk populations or spreading healthy lifestyles and disease prevention.
• Looking beyond mere hospitals and clinics, other realms include various establishments comprising other entities like laboratories, research organizations and pharmaceutical companies which had a part in the creation of technologies, drugs and vaccines relative to HBV. Still, analyzing the distribution of the HBV market by application provides insights into the numerous approaches to combating the many-faceted infection, as well as the various actors in the ecosystem. Reflecting on the kinds of assessment when it comes to HBV, the market offers a continuum of solutions that can be divided into identification of HBV antigens and antibodies, and deep molecular analysis that involves estimation of viral load and genomic profiling.
• Further, preventative measures also include the medications that treat the virus, immunomodulators and even possible treatment possibilities like gene therapy. Each of these analyses proves useful in managing HBV infection and is valuable for diagnosing patients, conducting ongoing surveillance, and discovering refinements in disease treatment. Nevertheless, to make the best strategic decisions at the clinical, research, and policy levels addressing the further development of HBV diagnostics and treatments and to minimize the burden of the disease in the world, it is crucial to have a clear understanding of the market segmentation by the type.

Hepatitis B Virus [HBV] Market  Regional Insights:

 Asia Pacific is Expected to Dominate the Market Over the Forecast period

• The Asia Pacific region shows a potential to dominate the Hepatitis B Virus (HBV) market in the forecast time. These are some of the reasons that make it possible to project an increased efficiency in mergers in the near future. To and I, firstly, the incidence rate of HBV in the Asia Pacific region is relatively high than in other region of the world and therefore the region is strategic in cases of treatment and management of the virus. The emergence of awareness in healthcare for Patients with HBV in addition to Government support and advancement in healthcare facilities the factors are promoting the Diagnostic, therapeutic and preventive measures for HBV.
• In addition, increasing economic development of countries such as China, India, and Soothe East Asian nations is increasing the demand for better healthcare services and improving access to them to increase the market as well. In addition, many leading market players are involved in the research and developmental undertakings in the Asia Pacific market in accordance with the requirements of the extent of the HBV among the Asia Pacific population. Thus, increased disease incidence, growing consciousness, better healthcare facilities, and increased research activities are expected to reshape the Asia Pacific region as the global market for HBV in the future.

Active Key Players in the Hepatitis B Virus [HBV] Market

• F. Hoffmann-La Roche Ltd (Switzerland)
• Merck & Co. Inc. . (US)
• Gilead Sciences Inc. . (US)
• AbbVie Inc. (US)
• Bristol Myers Squibb Company (US)
• Dicerna Pharmaceuticals (US)
• Arbutus Pharma (US)
• Novartis AG (Switzerland)
• AstraZeneca (UK)
• Bayer AG (Germany)
• Other Key Players

1. INTRODUCTION
   1. RESEARCH OBJECTIVES
   2. RESEARCH METHODOLOGY
   3. RESEARCH PROCESS
   4. SCOPE AND COVERAGE
      1. Market Definition
      2. Key Questions Answered
   5. MARKET SEGMENTATION
2. EXECUTIVE SUMMARY
3. MARKET OVERVIEW
4. GROWTH OPPORTUNITIES BY SEGMENT
5. MARKET LANDSCAPE
   1. PORTER’S FIVE FORCES ANALYSIS
      1. Bargaining Power Of Supplier
      2. Threat Of New Entrants
      3. Threat Of Substitutes
      4. Competitive Rivalry
      5. Bargaining Power Among Buyers
   2. INDUSTRY VALUE CHAIN ANALYSIS
   3. MARKET DYNAMICS
      1. Drivers
      2. Restraints
      3. Opportunities
      4. Challenges
   4. MARKET TREND ANALYSIS
   5. REGULATORY LANDSCAPE
   6. PESTLE ANALYSIS
   7. PRICE TREND ANALYSIS
   8. PATENT ANALYSIS
   9. TECHNOLOGY EVALUATION
   10. MARKET IMPACT OF THE RUSSIA-UKRAINE WAR
       1. Geopolitical Market Disruptions
       2. Supply Chain Disruptions
       3. Instability in Emerging Markets
   11. ECOSYSTEM
6. HEPATITIS B VIRUS [HBV] MARKET BY TYPE (2017-2032)
   1. HEPATITIS B VIRUS [HBV] MARKET SNAPSHOT AND GROWTH ENGINE
   2. MARKET OVERVIEW
   3. HEPATITIS B VIRUS (HBV) DNA TESTING
      1. Introduction And Market Overview
      2. Historic And Forecasted Market Size in Value (2017 – 2032F)
      3. Historic And Forecasted Market Size in Volume (2017 – 2032F)
      4. Key Market Trends, Growth Factors And Opportunities
      5. Geographic Segmentation Analysis
   4. HEPATITIS C VIRUS (HCV) RNA TESTING
   5. HUMAN IMMUNODEFICIENCY VIRUS (HIV) TYPES 1 AND 2 RNA TESTING
7. HEPATITIS B VIRUS [HBV] MARKET BY APPLICATION (2017-2032)
   1. HEPATITIS B VIRUS [HBV] MARKET SNAPSHOT AND GROWTH ENGINE
   2. MARKET OVERVIEW
   3. APPLICATIONA
      1. Introduction And Market Overview
      2. Historic And Forecasted Market Size in Value (2017 – 2032F)
      3. Historic And Forecasted Market Size in Volume (2017 – 2032F)
      4. Key Market Trends, Growth Factors And Opportunities
      5. Geographic Segmentation Analysis
   4. HOSPITAL
   5. CLINIC
   6. OTHERS
8. COMPANY PROFILES AND COMPETITIVE ANALYSIS
   1. COMPETITIVE LANDSCAPE
      1. Competitive Positioning
      2. Hepatitis B Virus [HBV] Market Share By Manufacturer (2023)
      3. Industry BCG Matrix
      4. Heat Map Analysis
      5. Mergers & Acquisitions
   2. F. HOFFMANN-LA ROCHE LTD (SWITZERLAND)
      1. Company Overview
      2. Key Executives
      3. Company Snapshot
      4. Role of the Company in the Market
      5. Sustainability and Social Responsibility
      6. Operating Business Segments
      7. Product Portfolio
      8. Business Performance (Production Volume, Sales Volume, Sales Margin, Production Capacity, Capacity Utilization Rate)
      9. Key Strategic Moves And Recent Developments
      10. SWOT Analysis
   3. MERCK & CO. INC. . (US)
   4. GILEAD SCIENCES INC. . (US)
   5. ABBVIE INC. (US)
   6. BRISTOL MYERS SQUIBB COMPANY (US)
   7. DICERNA PHARMACEUTICALS (US)
   8. ARBUTUS PHARMA (US)
   9. NOVARTIS AG (SWITZERLAND)
   10. ASTRAZENECA (UK)
   11. BAYER AG (GERMANY)
9. GLOBAL HEPATITIS B VIRUS [HBV] MARKET BY REGION
   1. OVERVIEW
   2. NORTH AMERICA
      1. Key Market Trends, Growth Factors And Opportunities
      2. Key Manufacturers
      3. Historic And Forecasted Market Size By Type
      4. Historic And Forecasted Market Size By Application
      5. Historic And Forecasted Market Size By Country
         1. USA
         2. Canada
         3. Mexico
   3. EASTERN EUROPE
      1. Key Market Trends, Growth Factors And Opportunities
      2. Key Manufacturers
      3. Historic And Forecasted Market Size By Segments
      4. Historic And Forecasted Market Size By Country
         1. Russia
         2. Bulgaria
         3. The Czech Republic
         4. Hungary
         5. Poland
         6. Romania
         7. Rest Of Eastern Europe
   4. WESTERN EUROPE
      1. Key Market Trends, Growth Factors And Opportunities
      2. Key Manufacturers
      3. Historic And Forecasted Market Size By Segments
      4. Historic And Forecasted Market Size By Country
         1. Germany
         2. United Kingdom
         3. France
         4. The Netherlands
         5. Italy
         6. Spain
         7. Rest Of Western Europe
   5. ASIA PACIFIC
      1. Key Market Trends, Growth Factors And Opportunities
      2. Key Manufacturers
      3. Historic And Forecasted Market Size By Segments
      4. Historic And Forecasted Market Size By Country
         1. China
         2. India
         3. Japan
         4. South Korea
         5. Malaysia
         6. Thailand
         7. Vietnam
         8. The Philippines
         9. Australia
         10. New-Zealand
         11. Rest Of APAC
   6. MIDDLE EAST & AFRICA
      1. Key Market Trends, Growth Factors And Opportunities
      2. Key Manufacturers
      3. Historic And Forecasted Market Size By Segments
      4. Historic And Forecasted Market Size By Country
         1. Turkey
         2. Bahrain
         3. Kuwait
         4. Saudi Arabia
         5. Qatar
         6. UAE
         7. Israel
         8. South Africa
   7. SOUTH AMERICA
      1. Key Market Trends, Growth Factors And Opportunities
      2. Key Manufacturers
      3. Historic And Forecasted Market Size By Segments
      4. Historic And Forecasted Market Size By Country
         1. Brazil
         2. Argentina
         3. Rest of South America
10. INVESTMENT ANALYSIS
11. ANALYST VIEWPOINT AND CONCLUSION
    1. Recommendations and Concluding Analysis
    2. Potential Market Strategies

LIST OF TABLES

TABLE 001. EXECUTIVE SUMMARY
TABLE 002. HEPATITIS B VIRUS [HBV] MARKET BARGAINING POWER OF SUPPLIERS
TABLE 003. HEPATITIS B VIRUS [HBV] MARKET BARGAINING POWER OF CUSTOMERS
TABLE 004. HEPATITIS B VIRUS [HBV] MARKET COMPETITIVE RIVALRY
TABLE 005. HEPATITIS B VIRUS [HBV] MARKET THREAT OF NEW ENTRANTS
TABLE 006. HEPATITIS B VIRUS [HBV] MARKET THREAT OF SUBSTITUTES
TABLE 007. HEPATITIS B VIRUS [HBV] MARKET BY DRUG CLASS
TABLE 008. NUCLEOTIDE ANALOG REVERSE TRANSCRIPTASE INHIBITORS MARKET OVERVIEW (2016-2028)
TABLE 009. MONOCLONAL ANTIBODY MARKET OVERVIEW (2016-2028)
TABLE 010. INTERFERON MARKET OVERVIEW (2016-2028)
TABLE 011. NON-STRUCTURAL PROTEIN 5A (NS5A) INHIBITORS MARKET OVERVIEW (2016-2028)
TABLE 012. NUCLEOTIDE ANALOG NS5B POLYMERASE INHIBITORS MARKET OVERVIEW (2016-2028)
TABLE 013. MULTI-CLASS COMBINATION MARKET OVERVIEW (2016-2028)
TABLE 014. OTHERS MARKET OVERVIEW (2016-2028)
TABLE 015. HEPATITIS B VIRUS [HBV] MARKET BY TYPE
TABLE 016. THERAPEUTICS MARKET OVERVIEW (2016-2028)
TABLE 017. VACCINE MARKET OVERVIEW (2016-2028)
TABLE 018. HEPATITIS B VIRUS [HBV] MARKET BY END USERS
TABLE 019. MEN MARKET OVERVIEW (2016-2028)
TABLE 020. WOMEN MARKET OVERVIEW (2016-2028)
TABLE 021. CHILDREN MARKET OVERVIEW (2016-2028)
TABLE 022. NORTH AMERICA HEPATITIS B VIRUS [HBV] MARKET, BY DRUG CLASS (2016-2028)
TABLE 023. NORTH AMERICA HEPATITIS B VIRUS [HBV] MARKET, BY TYPE (2016-2028)
TABLE 024. NORTH AMERICA HEPATITIS B VIRUS [HBV] MARKET, BY END USERS (2016-2028)
TABLE 025. N HEPATITIS B VIRUS [HBV] MARKET, BY COUNTRY (2016-2028)
TABLE 026. EUROPE HEPATITIS B VIRUS [HBV] MARKET, BY DRUG CLASS (2016-2028)
TABLE 027. EUROPE HEPATITIS B VIRUS [HBV] MARKET, BY TYPE (2016-2028)
TABLE 028. EUROPE HEPATITIS B VIRUS [HBV] MARKET, BY END USERS (2016-2028)
TABLE 029. HEPATITIS B VIRUS [HBV] MARKET, BY COUNTRY (2016-2028)
TABLE 030. ASIA PACIFIC HEPATITIS B VIRUS [HBV] MARKET, BY DRUG CLASS (2016-2028)
TABLE 031. ASIA PACIFIC HEPATITIS B VIRUS [HBV] MARKET, BY TYPE (2016-2028)
TABLE 032. ASIA PACIFIC HEPATITIS B VIRUS [HBV] MARKET, BY END USERS (2016-2028)
TABLE 033. HEPATITIS B VIRUS [HBV] MARKET, BY COUNTRY (2016-2028)
TABLE 034. MIDDLE EAST & AFRICA HEPATITIS B VIRUS [HBV] MARKET, BY DRUG CLASS (2016-2028)
TABLE 035. MIDDLE EAST & AFRICA HEPATITIS B VIRUS [HBV] MARKET, BY TYPE (2016-2028)
TABLE 036. MIDDLE EAST & AFRICA HEPATITIS B VIRUS [HBV] MARKET, BY END USERS (2016-2028)
TABLE 037. HEPATITIS B VIRUS [HBV] MARKET, BY COUNTRY (2016-2028)
TABLE 038. SOUTH AMERICA HEPATITIS B VIRUS [HBV] MARKET, BY DRUG CLASS (2016-2028)
TABLE 039. SOUTH AMERICA HEPATITIS B VIRUS [HBV] MARKET, BY TYPE (2016-2028)
TABLE 040. SOUTH AMERICA HEPATITIS B VIRUS [HBV] MARKET, BY END USERS (2016-2028)
TABLE 041. HEPATITIS B VIRUS [HBV] MARKET, BY COUNTRY (2016-2028)
TABLE 042. F HOFFMANN-LA ROCHE LTD: SNAPSHOT
TABLE 043. F HOFFMANN-LA ROCHE LTD: BUSINESS PERFORMANCE
TABLE 044. F HOFFMANN-LA ROCHE LTD: PRODUCT PORTFOLIO
TABLE 045. F HOFFMANN-LA ROCHE LTD: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 045. MERCK & CO. INC.: SNAPSHOT
TABLE 046. MERCK & CO. INC.: BUSINESS PERFORMANCE
TABLE 047. MERCK & CO. INC.: PRODUCT PORTFOLIO
TABLE 048. MERCK & CO. INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 048. GILEAD SCIENCES INC.: SNAPSHOT
TABLE 049. GILEAD SCIENCES INC.: BUSINESS PERFORMANCE
TABLE 050. GILEAD SCIENCES INC.: PRODUCT PORTFOLIO
TABLE 051. GILEAD SCIENCES INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 051. ABBVIE INC.: SNAPSHOT
TABLE 052. ABBVIE INC.: BUSINESS PERFORMANCE
TABLE 053. ABBVIE INC.: PRODUCT PORTFOLIO
TABLE 054. ABBVIE INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 054. BRISTOL MYERS SQUIBB COMPANY: SNAPSHOT
TABLE 055. BRISTOL MYERS SQUIBB COMPANY: BUSINESS PERFORMANCE
TABLE 056. BRISTOL MYERS SQUIBB COMPANY: PRODUCT PORTFOLIO
TABLE 057. BRISTOL MYERS SQUIBB COMPANY: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 057. DICERNA PHARMACEUTICALS: SNAPSHOT
TABLE 058. DICERNA PHARMACEUTICALS: BUSINESS PERFORMANCE
TABLE 059. DICERNA PHARMACEUTICALS: PRODUCT PORTFOLIO
TABLE 060. DICERNA PHARMACEUTICALS: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 060. ROCHE: SNAPSHOT
TABLE 061. ROCHE: BUSINESS PERFORMANCE
TABLE 062. ROCHE: PRODUCT PORTFOLIO
TABLE 063. ROCHE: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 063. ARBUTUS PHARMA: SNAPSHOT
TABLE 064. ARBUTUS PHARMA: BUSINESS PERFORMANCE
TABLE 065. ARBUTUS PHARMA: PRODUCT PORTFOLIO
TABLE 066. ARBUTUS PHARMA: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 066. NOVARTIS AG: SNAPSHOT
TABLE 067. NOVARTIS AG: BUSINESS PERFORMANCE
TABLE 068. NOVARTIS AG: PRODUCT PORTFOLIO
TABLE 069. NOVARTIS AG: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 069. ASTRAZENECA: SNAPSHOT
TABLE 070. ASTRAZENECA: BUSINESS PERFORMANCE
TABLE 071. ASTRAZENECA: PRODUCT PORTFOLIO
TABLE 072. ASTRAZENECA: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 072. BAYER AG: SNAPSHOT
TABLE 073. BAYER AG: BUSINESS PERFORMANCE
TABLE 074. BAYER AG: PRODUCT PORTFOLIO
TABLE 075. BAYER AG: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 075. OTHERS: SNAPSHOT
TABLE 076. OTHERS: BUSINESS PERFORMANCE
TABLE 077. OTHERS: PRODUCT PORTFOLIO
TABLE 078. OTHERS: KEY STRATEGIC MOVES AND DEVELOPMENTS

LIST OF FIGURES

FIGURE 001. YEARS CONSIDERED FOR ANALYSIS
FIGURE 002. SCOPE OF THE STUDY
FIGURE 003. HEPATITIS B VIRUS [HBV] MARKET OVERVIEW BY REGIONS
FIGURE 004. PORTER'S FIVE FORCES ANALYSIS
FIGURE 005. BARGAINING POWER OF SUPPLIERS
FIGURE 006. COMPETITIVE RIVALRYFIGURE 007. THREAT OF NEW ENTRANTS
FIGURE 008. THREAT OF SUBSTITUTES
FIGURE 009. VALUE CHAIN ANALYSIS
FIGURE 010. PESTLE ANALYSIS
FIGURE 011. HEPATITIS B VIRUS [HBV] MARKET OVERVIEW BY DRUG CLASS
FIGURE 012. NUCLEOTIDE ANALOG REVERSE TRANSCRIPTASE INHIBITORS MARKET OVERVIEW (2016-2028)
FIGURE 013. MONOCLONAL ANTIBODY MARKET OVERVIEW (2016-2028)
FIGURE 014. INTERFERON MARKET OVERVIEW (2016-2028)
FIGURE 015. NON-STRUCTURAL PROTEIN 5A (NS5A) INHIBITORS MARKET OVERVIEW (2016-2028)
FIGURE 016. NUCLEOTIDE ANALOG NS5B POLYMERASE INHIBITORS MARKET OVERVIEW (2016-2028)
FIGURE 017. MULTI-CLASS COMBINATION MARKET OVERVIEW (2016-2028)
FIGURE 018. OTHERS MARKET OVERVIEW (2016-2028)
FIGURE 019. HEPATITIS B VIRUS [HBV] MARKET OVERVIEW BY TYPE
FIGURE 020. THERAPEUTICS MARKET OVERVIEW (2016-2028)
FIGURE 021. VACCINE MARKET OVERVIEW (2016-2028)
FIGURE 022. HEPATITIS B VIRUS [HBV] MARKET OVERVIEW BY END USERS
FIGURE 023. MEN MARKET OVERVIEW (2016-2028)
FIGURE 024. WOMEN MARKET OVERVIEW (2016-2028)
FIGURE 025. CHILDREN MARKET OVERVIEW (2016-2028)
FIGURE 026. NORTH AMERICA HEPATITIS B VIRUS [HBV] MARKET OVERVIEW BY COUNTRY (2016-2028)
FIGURE 027. EUROPE HEPATITIS B VIRUS [HBV] MARKET OVERVIEW BY COUNTRY (2016-2028)
FIGURE 028. ASIA PACIFIC HEPATITIS B VIRUS [HBV] MARKET OVERVIEW BY COUNTRY (2016-2028)
FIGURE 029. MIDDLE EAST & AFRICA HEPATITIS B VIRUS [HBV] MARKET OVERVIEW BY COUNTRY (2016-2028)
FIGURE 030. SOUTH AMERICA HEPATITIS B VIRUS [HBV] MARKET OVERVIEW BY COUNTRY (2016-2028)